These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7970091)

  • 21. Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study.
    Watanabe Y; Akizawa T; Saito A; Gejyo F; Suzuki M; Nishizawa Y; Tomino Y; Tsubakihara Y; Akiba T; Hirakata H; Kawanishi H; Bessho M; Udagawa Y; Aoki K; Uemura Y; Ohashi Y;
    Ther Apher Dial; 2016 Dec; 20(6):598-607. PubMed ID: 27928910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of anemia with erythropoietin (rhuEPO) in patients with chronic kidney failure who are not yet in need of dialysis therapy].
    Wiecek A; Kokot F; Marcinkowski W; Rudka R; Klimek D
    Pol Arch Med Wewn; 1992 Nov; 88(5):310-23. PubMed ID: 1300551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
    Albitar S; Genin R; Fen-Chong M; Serveaux MO; Bourgeon B
    Nephrol Dial Transplant; 1998 May; 13(5):1206-10. PubMed ID: 9623555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
    Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
    Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation.
    Gordge MP; Leaker B; Patel A; Oviasu E; Cameron JS; Neild GH
    Thromb Res; 1990 Jan; 57(2):171-82. PubMed ID: 2315882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
    Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
    Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.
    Stefanidis I; Mertens PR; Wurth P; Bach R; Makropoulos W; Mann H; Heintz B
    Int J Artif Organs; 2001 Jun; 24(6):367-73. PubMed ID: 11482502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin.
    Bárány P; Pettersson E; Konarski-Svensson JK
    Nephrol Dial Transplant; 1993; 8(5):426-32. PubMed ID: 8393547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients.
    Kokot F; Wiecek A; Mesjasz J; Adamczak M; Spiechowicz U
    Nephrol Dial Transplant; 1998 May; 13(5):1200-5. PubMed ID: 9623554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin treatment in haemodialysis patients with iron overload.
    el-Reshaid K; Johny KV; Hakim A; Kamel H; Sebeta A; Hourani H; Kanyike FB
    Acta Haematol; 1994; 91(3):130-5. PubMed ID: 8091934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis.
    Alfurayh O; Sobh M; Barri Y; Qunibi W; Taher S
    Nephrol Dial Transplant; 1992; 7(9):939-43. PubMed ID: 1328942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin.
    Horina JH; Schwaberger G; Brussee H; Sauseng-Fellegger G; Holzer H; Krejs GJ
    Nephrol Dial Transplant; 1993; 8(11):1219-22. PubMed ID: 8302459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure and heart rate in chronic haemodialysis patients.
    van de Borne P; Tielemans C; Vanherweghem JL; Degaute JP
    Nephrol Dial Transplant; 1992; 7(1):45-9. PubMed ID: 1316580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
    Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelin in chronic renal failure.
    Takahashi K; Totsune K; Mouri T
    Nephron; 1994; 66(4):373-9. PubMed ID: 8015637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rHuEpo therapy in dialysis patients on endogenous erythropoietin synthesis after renal transplantation.
    Fernández Lucas M; Marcén R; Villafruela J; Teruel JL; Tato A; Rivera M; Ortuño J
    Nephron; 1996; 73(1):54-7. PubMed ID: 8742957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
    Reuter SE; Faull RJ; Ranieri E; Evans AM
    Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ketanserin decreases erythropoietin concentration in hemodialyzed patients on rHuEPO therapy].
    Borawski J; Mazerska M; Pawlak K; Myśliwiec M
    Pol Arch Med Wewn; 1994; 92 Spec No():14-20. PubMed ID: 7731894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.